The New York Times interviewed our founder, Jennifer Miller, on FDA Commissioner Dr. Scott Gottlieb’s clinical trial transparency initiatives. She discussed his new pilot, launched last month, which selects 9 recently-approved drugs, whose sponsors (generally pharmaceutical companies) volunteer to participate, to post portions of Clinical Study Reports (CSRs) from their pivotal trials on FDA’s website Drugs@FDA. Read more about the FDA pilot in its press release, here.
The New York Time article, by Sheila Kaplan and Katie Thomas, also reviews Dr. Gottlieb’s extensive experience working in several sectors across healthcare innovation and delivery- ranging from venture capital to board membership in a tobacco related company- as well as his successes straddling political, corporate, and public health interests.
Senator Elizabeth Warren, Democrat of Massachusetts, applauds Dr. Gottlieb’s willingness “to tackle tough problems,” in the article. Our founder Jennifer Miller, also applauds him, stating that his pilot program is a step in the right direction. “The industry is already trending toward releasing them (CSRs),” Dr. Miller said. “It’s a safe time to roll out a pilot. I think he’ll likely be successful and learn what works and what didn’t.” Read the NYT article, here.